Patients with advanced-stage lung cancer might discontinue immune-checkpoint inhibitor (ICI) treatment for various reasons, including toxicities, disease progression or disease remission. Nonetheless, treatment options in this setting are often limited and some patients might derive benefit from re-administration of a previously received ICI. In this Review, the authors summarize the available data on ICI rechallenge, including the reasons for discontinuation and the feasibility of rechallenge in various clinical scenarios, and highlight important unaddressed research questions.
- Li-Bo Tang
- Ying-Long Peng
- Qing Zhou
